Want to join the conversation?
Excluding 3Q14 clinical trials revenue, $DGX's consolidated revenue was $1.88Bil, up by 0.9% vs. 3Q14 on an equivalent revenue basis. GAAP reported revenues were lower by 1.3%, while diagnostic information services revenue was flat to prior year. Revenue per acquisition was 0.2% better than 3Q14.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?